Form 4: Third Rock Ventures IV, L.P. Sells 67,400 Shares of Tango Therapeutics, Inc. (TNGX)

Third Rock Ventures IV, L.P. reports the sale of 67,400 shares of Tango Therapeutics, Inc. at a weighted average price of $10.5305 per share.

Summary

• On September 13, 2024, Third Rock Ventures IV, L.P. sold 67,400 shares of Tango Therapeutics, Inc. (TNGX) common stock.
• The shares were sold at prices ranging from $10.50 to $10.74 per share, with a weighted average price of $10.5305.
• Following the transaction, Third Rock Ventures IV, L.P. directly holds 16,859,075 shares of Tango Therapeutics, Inc.
• The reporting entities include Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC.
• Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a standard transaction by a major shareholder. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

This filing indicates a transaction by a major shareholder, which is common in the biotech industry as venture capital firms manage their investments. It's important to monitor such transactions to understand investor sentiment and potential impact on the stock's price.

Comparison to Industry Standards

• Venture capital firms like Third Rock Ventures often take significant stakes in biotech companies and periodically adjust their holdings.
• Sales of this nature are typical as funds mature and seek to return capital to their investors.
• Comparing the size and frequency of these transactions to similar firms like Flagship Pioneering or ARCH Venture Partners can provide context.

Stakeholder Impact

• Shareholders may react to the news of a major shareholder selling shares, potentially impacting the stock price in the short term.
• The transaction itself doesn't directly impact employees, customers, suppliers, or creditors.

Key Dates